Biotech Series C Investors & VC Firms
430 firms in this list, with a median first check of $648K. 101 of them lead rounds. Generated from verified public data and updated continuously.
Samsara BioCapital
Menlo ParkSeed–Series C
42 people
Basecamp Fund
ManchesterPre-Seed–Late Stage$100K – $10M
15 people
Prime Movers Lab
JacksonSeed–Growth$2M – $30M
45 people
Sofina
BrusselsSeed–Late Stage$100M – $300M
57 people
Hatteras Venture Partners
Research TriangleSeed–Series C$500K – $4M
23 people
M Ventures
AmsterdamSeed–Growth$10.8M
25 people
Seventure Partners
ParisSeed–Growth
19 people
Celesta Capital
San MateoPre-Seed–Series C$5M – $10M
26 people
HealthCap
StockholmSeed–Growth
33 people
Granite Asia
SingaporeSeed–Late Stage$5M – $25M
35 people
Nextech Invest
ZurichSeed–Late Stage$648K – $3.2M
43 people
Amadeus Capital Partners
LondonPre-Seed–Growth$50K – $12.7M
28 people
Optum Ventures
BostonSeed–Growth
35 people
Catalio Capital Management, LP
New YorkSeed–Late Stage
37 people
Hercules Capital, Inc.
San MateoSeries C–Late Stage
51 people
OUP (Osage University Partners)
Bala CynwydPre-Seed–Late Stage$1M – $20M
21 people
US Venture Partners
Menlo ParkSeed–Series C$500K – $10M
12 people
Forbion
NaardenPre-Seed–Late Stage
25 people
Bain Capital Life Sciences
BostonSeries B–Late Stage
31 people
Casdin Capital
New YorkSeed–Series C
38 people
Abingworth
LondonSeed–Series C$15M – $30M
43 people
Johnson & Johnson Innovation – JJDC
New BrunswickSeed–Growth
42 people
Nazca
Mexico CityPre-Seed–Late Stage
32 people
Vida Ventures
Los AngelesPre-Seed–Late Stage
45 people
Related lists
Biotech Investors & VC Firms (2504)Biotech Seed Investors & VC Firms (2043)Series C Investors & VC Firms (1709)Biotech Series A Investors & VC Firms (1638)Biotech Investors & VC Firms in North America (1618)Biotech Investors & VC Firms in United States (1466)Biotech Investors & VC Firms in Europe (961)Series C Investors & VC Firms in North America (942)Biotech Pre-Seed Investors & VC Firms (931)Biotech Investors & VC Firms in Global (826)
Data sourced from public filings and firms' own websites — see our methodology.















































































































